Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 18/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984949 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL23710407 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL21582882 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL18458206 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL6883789 | 1.00 | METAP2 (0.81) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL13799962 | 0.94 | METAP2 (0.78) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL19880170 | 0.94 | METAP2 (0.82) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL18458208 | 0.94 | METAP2 (0.82) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL21017027 | 0.93 | METAP2 (0.76) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL21880698 | 0.93 | METAP2 (0.76) | METAP2ABCB11LMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803382-B2 | 1-OXASPIRO(2,5)OCTAN-6-OL DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-10-12 | — | — | US | disclosed |
| US-20030134896-A1 | Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134896-A1 | Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof | VEGFA, KDR, FLT1 | METAP2 2357/4885ABCB11 4291/4885LMNA 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.